Global Gabapentin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gabapentin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Gabapentin report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gabapentin market is projected to reach US$ 1749.7 million in 2034, increasing from US$ 1542 million in 2022, with the CAGR of 1.8% during the period of 2024 to 2034. Demand from Epilepsy and Neuropathic Pain are the major drivers for the industry.
Global Gabapentin key players include Novartis, TEVA, Mylan, Pfizer, etc. Global top four manufacturers hold a share about 20%.
North America is the largest market, with a share over 30%, followed by Asia-Pacific, and Europe, both have a share about 50 percent.
In terms of product, Capsule is the largest segment, with a share about 55%. And in terms of application, the largest application is Epilepsy, followed by Neuropathic Pain, Restless Legs Syndrome, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gabapentin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Assertio Therapeutics
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike
Segment by Type
Capsule
Tablet
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Gabapentin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gabapentin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gabapentin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gabapentin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gabapentin introduction, etc. Gabapentin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Gabapentin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Gabapentin report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gabapentin market is projected to reach US$ 1749.7 million in 2034, increasing from US$ 1542 million in 2022, with the CAGR of 1.8% during the period of 2024 to 2034. Demand from Epilepsy and Neuropathic Pain are the major drivers for the industry.
Global Gabapentin key players include Novartis, TEVA, Mylan, Pfizer, etc. Global top four manufacturers hold a share about 20%.
North America is the largest market, with a share over 30%, followed by Asia-Pacific, and Europe, both have a share about 50 percent.
In terms of product, Capsule is the largest segment, with a share about 55%. And in terms of application, the largest application is Epilepsy, followed by Neuropathic Pain, Restless Legs Syndrome, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gabapentin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Assertio Therapeutics
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike
Segment by Type
Capsule
Tablet
Segment by Application
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Gabapentin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gabapentin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gabapentin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gabapentin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gabapentin introduction, etc. Gabapentin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Gabapentin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices